Business
Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies
New license agreement expands Genprex’s oncology franchise Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy
About this update from Genprex, Inc.
[{"type":"text","content":"\nNew license agreement expands Genprex’s oncology franchise \n\n\nLicensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs, including:\n\n\n\nPembrolizumab (Merck’s largest selling drug Keytruda®)\n\n\nNivolumab (Bristol-Myers Squibb’s Opdivo®)\n\n\nIpilimumab (Bristol-Myers Squibb’s Yervoy®)\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nGenprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it has entered into a Patent and Technology License Agreement (“License Agreement”) with The University of Texas MD Anderson Cancer Center (“MD Anderson”) in which MD Anderson granted to Genprex an exclusive worldwide license to a portfolio of 16 patent applications and related technology (“Licensed IP”) for the treatment of cancer using Genprex’s lead drug candidate and TUSC2 gene therapy, known as “Oncoprex” or “GEN-001,” in combination with immunotherapies. This is a distinct therapeutic approach from that of combining Oncoprex with targeted therapies such as osimertinib (marketed as Tagrisso® by AstraZeneca).\n\n\nGenprex was recently awarded U.S. FDA Fast Track designation for use of Oncoprex combined with Tagrisso for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations whose tumors progressed after treatment with Tagrisso alone. The Company is now preparing to file an Investigational New Drug application to initiate a clinical trial of Oncoprex in combination with pembrolizumab (marketed as Keytruda® by Merck) in NSCLC.\n\n\n“We are pleased to advance the intellectual property that is covered by this License Agreement,” said Rodney Varner, Genprex’s Chairman and Chief Executive Officer. “We are excited to be developing two distinct therapeutic approaches to lung cancer utilizing the combination of our gene therapy with successful targeted therapies, such as Tagrisso, and immunotherapies, such as Keytruda, to potentially improve patient outcomes and increase the number of patients who may benefit from these important therapies.”\n\n\nImmunotherapy or immunotherapy combined with chemotherapy is now the first-line standard of care for the majority of lung cancer patients. Published preclinical data indicate that when Oncopr...